Talk to Alison
00 1 718 618 48 97
Search inside this page
Top countries
Publication dates
Publishers
All regions
data types
Free Market Research Guides to Download
» Purchase Premium Reports
241-280 of about 3 800 reports
BMI View: We continue viewing Iran as one of the less attractive regional industries. Imposition of more stringent international sanctions, rampant inflation, and the loss of confidence in the Iranian ...
BMI View: Peru's large and growing population underpins the potential of its pharmaceutical industry , especially given the rising prevalence of non-communicable diseases. However, Peru remains listed ...
Includes 3 FREE quarterly updates BMI View: Despite an increasingly ageing population (consequently increasing burden of noncommunicable diseases), Hong Kong will only be moderately attractive to investors ...
Includes 3 FREE quarterly updates BMI View: Corruption continues to be a major problem within state healthcare services in Serbia. The government are taking measures to tackle the issue but the pharmaceutical ...
Includes 3 FREE quarterly updates BMI View: Indonesia is a high growth pharmaceutical industry driven by rising domestic consumption and government spending on healthcare. Having said this, the prevalence ...
Includes 3 FREE quarterly updates BMI View: South Africa is one of the most developed industry s in the region from a business environment and regulatory standpoint. However, vast income disparity within ...
BMI View: Moldova's pharmaceutical industry recorded stronger growth in 2011, but its small industry size and its status as the poorest countries in Europe limit its attractiveness as a destination fo ...
Includes 3 FREE quarterly updates BMI View: India's pharmaceutical industry is highly attractive to drugmakers but it also has several negative characteristics. Combined revenues of over-the-counter (OTC) ...
Includes 3 FREE quarterly updates BMI View: New population data for 2011 show the size of the expatriate population in the United Arab Emirates (UAE) has been underappreciated. Population growth has fed ...
Includes 3 FREE quarterly updates BMI View: Venezuela's pharmaceutical market will face increasingly harsh pricing policy which is unlikely to tackle the persistent medicine shortage problem. President ...
Includes 3 FREE quarterly updates BMI View: Bahrain is a developed pharmaceutical industry with patented drug spending accounting for over 83% of the total pharmaceutical expenditure in 2011. However, ...
BMI View: Despite the threat of austerity measures and the government's focus on cost-containment within the pharmaceuticals and healthcare segment, as well as the impact of generic competition as a result ...
BMI View: Measured in local currency and in US dollars, the value of Argentina's pharmaceutical industry is expected to grow at double-digit rates over the five years to 2016, in large part due to inflationary ...
Includes 3 FREE quarterly updates BMI View: Belgium, much like most of the other regional industries, is expected to post negative year-onyear (y-o-y) value growth in its 2012 pharmaceutical revenues because ...
BMI View: Historical underinvestment in the Kenyan healthcare segment and its high growth projection - driven by strong demographics, increased healthcare needs, longer life expectancy, increased healthcare ...
BMI View: While the Turkish pharmaceutical market has achieved some concessions following additional price cuts and public discounts announced in November 2011, the impact of the November decree remains ...
Includes 3 FREE quarterly updates BMI View: Given the country's increasingly ageing population and the consequential rise in noncommunicable diseases, Australia is a highly attractive place for multinational ...
Includes 3 FREE quarterly updates BMI View: Mexico offers significant and improving opportunities for multinational pharmaceutical firms, especially in the outperforming generic medicine and improving ...
Includes 3 FREE quarterly updates BMI View: The operational environment for drugmakers in Pakistan has worsened over the past year, partly as a result of the dissolution of the Ministry of Health (MoH) ...
Includes 3 FREE quarterly updates BMI View: While the strength of the UK's pharmaceutical manufacturing market is significant, the segment will face considerable challenges over the coming years. Economic ...
Includes 3 FREE quarterly updates BMI View: Low growth potential in New Zealand's pharmaceutical market will attract risk-averse investors. However, we note that regulatory delays in funding new medicines ...
Includes 3 FREE quarterly updates BMI View: The prospects for Japan's pharmaceutical industry over the medium term are very positive. The country has one of the largest pensionable populations, healthcare ...
Includes 3 FREE quarterly updates BMI View: The Nigerian pharmaceutical industry continues to be seen as a risky proposition to multinationals. While the country's oil revenues are significant, income ...
Includes 3 FREE quarterly updates BMI View: We stand by our negative projection for the Croatian pharmaceutical industry in 2012, on the back of the weakening economy and wide-ranging cost-containment ...
Includes 3 FREE quarterly updates BMI View: We retain our negative outlook for the pharmaceutical industry in the Czech Republic, expecting a 1.8% contraction in its value in local currency terms in 2012, ...
BMI View: Following Qatar's decision to reintroduce controls on medicine prices in late 2011, we expect pharmaceutical price inflation to moderate. Consequently, industry growth rates in 2012 will be at ...
BMI View: Puerto Rico is struggling to retain its reputation as a pharmaceutical manufacturing hub, with a number of plants found to be in breach of regulations and standards over recent years. Additionally, ...
Includes 3 FREE quarterly updates BMI View: We continue to believe the Belarusian pharmaceutical industry has long-term potential due to the country's favourable geographic position, demographic profile ...
Includes 3 FREE quarterly updates BMI View: Chile's pharmaceutical industry is expected to become an increasingly attractive proposition for multinational industry players as regulatory and intellectual ...
BMI View: Economics and politics are increasingly exerting an influence on the US pharmaceutical market. This is in stark contrast to the late 1990s and early 2000s, when the business environment was ...
Yearly, From 2006 To 2010
By Chinascope Financial
Source: Chinascope Financial
Yearly, From 2006 To 2010
By Chinascope Financial
Source: Chinascope Financial
Yearly, From 2000 To 2011
By Chinascope Financial
Source: Chinascope Financial
Yearly, From 2006 To 2010
By Chinascope Financial
Source: Chinascope Financial
Yearly, From 2006 To 2010
By Chinascope Financial
Source: Chinascope Financial
Yearly, From 2006 To 2010
By Chinascope Financial
Source: Chinascope Financial
Yearly, From 2000 To 2011
By Chinascope Financial
Source: Chinascope Financial
Yearly, From 2006 To 2010
By Chinascope Financial
Source: Chinascope Financial
Yearly, From 2006 To 2010
By Chinascope Financial
Source: Chinascope Financial
Yearly, From 1986 To 2011
By Chinascope Financial
Source: Chinascope Financial
» Download Public Reports
About 11 000 reports
Monthly, From 1992 To 2012
Source: U.S. Department of Commerce: Census Bureau
» Read our Company Profiles
70 CompaniesReportlinker.com © Copyright 2013. All rights reserved.